Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 2
2020 2
2021 3
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
EASIX-1year and late mortality after allogeneic stem cell transplantation.
Kordelas L, Terzer T, Gooley T, Davis C, Sandmaier BM, Sorror M, Penack O, Schaeper NDE, Blau IW, Beelen D, Radujkovic A, Dreger P, Luft T. Kordelas L, et al. Blood Adv. 2023 Sep 26;7(18):5374-5381. doi: 10.1182/bloodadvances.2022008617. Blood Adv. 2023. PMID: 37477588 Free PMC article.
Brier score and c-index analyses validated the univariable EASIX effects. There was no significant interaction between EASIX-1year and incidence of chronic graft-versus-host disease (GVHD) on OS. EASIX-1year predicted the outcome irrespective of preexisting c …
Brier score and c-index analyses validated the univariable EASIX effects. There was no significant interaction between EASIX-1 …
EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study.
Korell F, Penack O, Mattie M, Schreck N, Benner A, Krzykalla J, Wang Z, Schmitt M, Bullinger L, Müller-Tidow C, Dreger P, Luft T. Korell F, et al. Front Immunol. 2022 Apr 8;13:877477. doi: 10.3389/fimmu.2022.877477. eCollection 2022. Front Immunol. 2022. PMID: 35464403 Free PMC article.
The primary objective was to assess the predictive capacity of EASIX measured immediately before the start of lymphodepletion (EASIX-pre) for the occurrence of grade 3 CRS and/or ICANS. ...Serum endothelial distress markers measured on day+7 correlated with EASIX …
The primary objective was to assess the predictive capacity of EASIX measured immediately before the start of lymphodepletion (EAS …
EASIX and mortality after allogeneic stem cell transplantation.
Luft T, Benner A, Terzer T, Jodele S, Dandoy CE, Storb R, Kordelas L, Beelen D, Gooley T, Sandmaier BM, Sorror M, Zeisbrich M, Radujkovic A, Dreger P, Penack O. Luft T, et al. Bone Marrow Transplant. 2020 Mar;55(3):553-561. doi: 10.1038/s41409-019-0703-1. Epub 2019 Sep 26. Bone Marrow Transplant. 2020. PMID: 31558788 Free PMC article.
We performed a retrospective cohort analysis in five alloSCT centers in the USA and Germany. EASIX was assessed prior to conditioning (EASIX-pre) and correlated with mortality in 755 patients of a training cohort in multivariable models. ...We found that EASIX …
We performed a retrospective cohort analysis in five alloSCT centers in the USA and Germany. EASIX was assessed prior to conditioning …
EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients.
Luft T, Wendtner CM, Kosely F, Radujkovic A, Benner A, Korell F, Kihm L, Bauer MF, Dreger P, Merle U. Luft T, et al. Front Immunol. 2021 Jun 23;12:634416. doi: 10.3389/fimmu.2021.634416. eCollection 2021. Front Immunol. 2021. PMID: 34248931 Free PMC article.
Aim of this study was to test if EASIX could predict life-threatening complications in patients with COVID-19. ...CONCLUSION: EASIX is a validated predictor of COVID19 outcome and an easy-to-access tool to segregate patients in need for intensive surveillance....
Aim of this study was to test if EASIX could predict life-threatening complications in patients with COVID-19. ...CONCLUSION: EASI …
Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study.
Penack O, Luft T, Peczynski C, Benner A, Sica S, Arat M, Itäla-Remes M, Corral LL, Schaap NPM, Karas M, Raida L, Schroeder T, Dreger P, Metafuni E, Ozcelik T, Sandmaier BM, Kordelas L, Moiseev I, Schoemans H, Koenecke C, Basak GW, Peric Z. Penack O, et al. J Immunother Cancer. 2024 Jan 9;12(1):e007635. doi: 10.1136/jitc-2023-007635. J Immunother Cancer. 2024. PMID: 38199608 Free PMC article.
RESULTS: Twenty-three % (n=74) of alloSCT recipients had EASIX-pre 3 taken before conditioning. NRM at 2 years was 31.1% in the high EASIX group versus 11.5% in the low EASIX group (p<0.001). Patients with high EASIX-pre also had worse 2 years overa …
RESULTS: Twenty-three % (n=74) of alloSCT recipients had EASIX-pre 3 taken before conditioning. NRM at 2 years was 31.1% in the high …
EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis.
Luft T, Benner A, Jodele S, Dandoy CE, Storb R, Gooley T, Sandmaier BM, Becker N, Radujkovic A, Dreger P, Penack O. Luft T, et al. Lancet Haematol. 2017 Sep;4(9):e414-e423. doi: 10.1016/S2352-3026(17)30108-4. Epub 2017 Jul 18. Lancet Haematol. 2017. PMID: 28733186
The primary endpoint was prediction of overall survival when measured at acute GVHD onset (EASIX-GVHD). We validated the prognostic strength of EASIX-GVHD for overall survival and non-relapse mortality in the three independent cohorts by calculating the prediction e …
The primary endpoint was prediction of overall survival when measured at acute GVHD onset (EASIX-GVHD). We validated the prognostic s …
Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation.
Korell F, Schreck N, Müller-Tidow C, Dreger P, Luft T; Taskforce allogeneic Stem Cell Transplantation, University Hospital Heidelberg. Korell F, et al. Intensive Care Med. 2022 Jun;48(6):753-755. doi: 10.1007/s00134-022-06676-3. Epub 2022 Apr 16. Intensive Care Med. 2022. PMID: 35429256 Free PMC article. No abstract available.
EASIX for prediction of survival in lower-risk myelodysplastic syndromes.
Merz A, Germing U, Kobbe G, Kaivers J, Jauch A, Radujkovic A, Hummel M, Benner A, Merz M, Dreger P, Luft T. Merz A, et al. Blood Cancer J. 2019 Nov 11;9(11):85. doi: 10.1038/s41408-019-0247-z. Blood Cancer J. 2019. PMID: 31712595 Free PMC article. Clinical Trial.
Serum markers of endothelial cell distress were measured and correlated to EASIX. While no effects of EASIX on survival were observed in higher-risk patients, EASIX was associated with shorter survival in patients with lower-risk MDS in both cohorts (univaria …
Serum markers of endothelial cell distress were measured and correlated to EASIX. While no effects of EASIX on survival were o …
Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel.
Jiang S, Penack O, Terzer T, Schult D, Majer-Lauterbach J, Radujkovic A, Blau IW, Bullinger L, Müller-Tidow C, Dreger P, Luft T. Jiang S, et al. Haematologica. 2021 Feb 1;106(2):446-453. doi: 10.3324/haematol.2019.238790. Haematologica. 2021. PMID: 31974195 Free PMC article.
The protective effect was most pronounced in patients with high EASIX-d0. The cumulative SOS/VOD incidence in the highest EASIX-d0 quartiles were 18.1% and 16.8% in both cohorts without endothelial prophylaxis as compared to 2.2% in patients with pravastatin/UDA pro …
The protective effect was most pronounced in patients with high EASIX-d0. The cumulative SOS/VOD incidence in the highest EASIX …
13 results